0001209191-23-014589.txt : 20230302
0001209191-23-014589.hdr.sgml : 20230302
20230302160547
ACCESSION NUMBER: 0001209191-23-014589
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230301
FILED AS OF DATE: 20230302
DATE AS OF CHANGE: 20230302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Delaney Brendan
CENTRAL INDEX KEY: 0001722585
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 23698852
MAIL ADDRESS:
STREET 1: 300 THE AMERICAN WAY
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aadi Bioscience, Inc.
CENTRAL INDEX KEY: 0001422142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 611547850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
BUSINESS PHONE: 424-473-8055
MAIL ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
FORMER COMPANY:
FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20170316
FORMER COMPANY:
FORMER CONFORMED NAME: ZETA ACQUISITION CORP II
DATE OF NAME CHANGE: 20071227
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-01
0
0001422142
Aadi Bioscience, Inc.
AADI
0001722585
Delaney Brendan
C/O AADI BIOSCIENCE, INC.
17383 SUNSET BOULEVARD, SUITE A250
PACIFIC PALISADES
CA
90272
1
1
0
0
See remarks
Stock option (right to buy)
10.93
2023-03-01
4
A
0
235000
0.00
A
2033-03-01
Common Stock
235000
235000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2023.
President and Chief Executive Officer
/s/ Stephen Rodin, as Attorney-in-Fact
2023-03-02